NLRP3 and melanoma: The expansion of MDSCs is induced in melanoma through NLRP3/IL-1 signaling, suggesting that NLRP3 inhibitors may restore T cell function through reducing the numbers of tumor MDSCs, and the combined treatment with NLRP3 inhibitor and anti-PD-1 is more effective (55).